These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 23016878

  • 1. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
    Else M, Marín-Niebla A, de la Cruz F, Batty P, Ríos E, Dearden CE, Catovsky D, Matutes E.
    Br J Haematol; 2012 Nov; 159(3):322-8. PubMed ID: 23016878
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
    Bennett M, Schechter GP.
    Semin Hematol; 2010 Apr; 47(2):143-7. PubMed ID: 20350661
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
    Cervetti G, Galimberti S, Pelosini M, Ghio F, Cecconi N, Petrini M.
    Ann Oncol; 2013 Sep; 24(9):2434-8. PubMed ID: 23712547
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma.
    Orciuolo E, Buda G, Sordi E, Baraté C, Galimberti S, Ciancia E, Petrini M.
    Leuk Res; 2010 Feb; 34(2):184-9. PubMed ID: 19414190
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
    Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C.
    Cancer; 2009 Nov 15; 115(22):5210-7. PubMed ID: 19672998
    [Abstract] [Full Text] [Related]

  • 12. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.
    Iannitto E, Minardi V, Calvaruso G, Ammatuna E, Florena AM, Mulè A, Tripodo C, Quintini G, Abbadessa V.
    Eur J Haematol; 2005 Aug 15; 75(2):130-5. PubMed ID: 16000129
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
    Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST.
    Ann Hematol; 2011 Oct 15; 90(10):1219-23. PubMed ID: 21520001
    [Abstract] [Full Text] [Related]

  • 20. Rituximab monotherapy for splenic marginal zone lymphoma with villous lymphocytes: report on long-term disease control for two patients with recurrence after splenectomy.
    Debiasi M, Hehnemann M, Garicochea B.
    Sao Paulo Med J; 2010 Dec 15; 128(6):375-7. PubMed ID: 21308163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.